Transgene SA
PAR:TNG

Watchlist Manager
Transgene SA Logo
Transgene SA
PAR:TNG
Watchlist
Price: 0.788 EUR 0.77% Market Closed
Market Cap: 104m EUR
Have any thoughts about
Transgene SA?
Write Note

Intrinsic Value

TNG's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one TNG stock under the Base Case scenario is 1.098 EUR. Compared to the current market price of 0.788 EUR, Transgene SA is Undervalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TNG Intrinsic Value
1.098 EUR
Undervaluation 28%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Transgene SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TNG cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TNG?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Transgene SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Transgene SA

Provide an overview of the primary business activities
of Transgene SA.

What unique competitive advantages
does Transgene SA hold over its rivals?

What risks and challenges
does Transgene SA face in the near future?

Has there been any significant insider trading activity
in Transgene SA recently?

Summarize the latest earnings call
of Transgene SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Transgene SA.

Provide P/S
for Transgene SA.

Provide P/E
for Transgene SA.

Provide P/OCF
for Transgene SA.

Provide P/FCFE
for Transgene SA.

Provide P/B
for Transgene SA.

Provide EV/S
for Transgene SA.

Provide EV/GP
for Transgene SA.

Provide EV/EBITDA
for Transgene SA.

Provide EV/EBIT
for Transgene SA.

Provide EV/OCF
for Transgene SA.

Provide EV/FCFF
for Transgene SA.

Provide EV/IC
for Transgene SA.

Show me price targets
for Transgene SA made by professional analysts.

What are the Revenue projections
for Transgene SA?

How accurate were the past Revenue estimates
for Transgene SA?

What are the Net Income projections
for Transgene SA?

How accurate were the past Net Income estimates
for Transgene SA?

What are the EPS projections
for Transgene SA?

How accurate were the past EPS estimates
for Transgene SA?

What are the EBIT projections
for Transgene SA?

How accurate were the past EBIT estimates
for Transgene SA?

Compare the revenue forecasts
for Transgene SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Transgene SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Transgene SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Transgene SA compared to its peers.

Compare the P/E ratios
of Transgene SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Transgene SA with its peers.

Analyze the financial leverage
of Transgene SA compared to its main competitors.

Show all profitability ratios
for Transgene SA.

Provide ROE
for Transgene SA.

Provide ROA
for Transgene SA.

Provide ROIC
for Transgene SA.

Provide ROCE
for Transgene SA.

Provide Gross Margin
for Transgene SA.

Provide Operating Margin
for Transgene SA.

Provide Net Margin
for Transgene SA.

Provide FCF Margin
for Transgene SA.

Show all solvency ratios
for Transgene SA.

Provide D/E Ratio
for Transgene SA.

Provide D/A Ratio
for Transgene SA.

Provide Interest Coverage Ratio
for Transgene SA.

Provide Altman Z-Score Ratio
for Transgene SA.

Provide Quick Ratio
for Transgene SA.

Provide Current Ratio
for Transgene SA.

Provide Cash Ratio
for Transgene SA.

What is the historical Revenue growth
over the last 5 years for Transgene SA?

What is the historical Net Income growth
over the last 5 years for Transgene SA?

What is the current Free Cash Flow
of Transgene SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Transgene SA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Transgene SA

Current Assets 19.1m
Cash & Short-Term Investments 15.3m
Receivables 1.8m
Other Current Assets 2m
Non-Current Assets 31.6m
Long-Term Investments 657k
PP&E 14.1m
Intangibles 74k
Other Non-Current Assets 16.8m
Current Liabilities 12.2m
Accounts Payable 7.3m
Accrued Liabilities 3m
Other Current Liabilities 1.9m
Non-Current Liabilities 39.2m
Other Non-Current Liabilities 39.2m
Efficiency

Earnings Waterfall
Transgene SA

Revenue
7.8m EUR
Operating Expenses
-37.4m EUR
Operating Income
-29.6m EUR
Other Expenses
8.3m EUR
Net Income
-21.3m EUR

Free Cash Flow Analysis
Transgene SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

TNG Profitability Score
Profitability Due Diligence

Transgene SA's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

16/100
Profitability
Score

Transgene SA's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

TNG Solvency Score
Solvency Due Diligence

Transgene SA's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
49/100
Solvency
Score

Transgene SA's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TNG Price Targets Summary
Transgene SA

Wall Street analysts forecast TNG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TNG is 2.992 EUR with a low forecast of 2.222 EUR and a high forecast of 4.2 EUR.

Lowest
Price Target
2.222 EUR
182% Upside
Average
Price Target
2.992 EUR
280% Upside
Highest
Price Target
4.2 EUR
433% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TNG?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for TNG is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TNG Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Transgene SA Logo
Transgene SA

Country

France

Industry

Biotechnology

Market Cap

104m EUR

Dividend Yield

0%

Description

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 167 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Contact

GRAND EST
Illkirch-Graffenstaden
400 Boulevard Gonthier d'Andernach, Parc d'Innovation - CS80166
+33388279100.0
www.transgene.fr

IPO

1998-03-25

Employees

167

Officers

CEO & Chairman of the Board
Dr. Alessandro Riva M.D.
Chief Financial Officer
Ms. Lucie Larguier
Vice President & Chief Scientific Officer
Dr. Maurizio Ceppi
VP, General Counsel & Corporate Secretary
Mr. John Felitti J.D., LLM
Chief Human Resources Officer
Ms. Christelle Schwoerer
VP & Chief Business Officer
Mr. James Wentworth M.B.A., Ph.D.
Show More
VP of Medical Affairs & Chief Medical Officer
Ms. Emmanuelle Dochy M.D.
VP & Director of Human Resources
Ms. Gaelle Stadtler
Project Leader of Personalized Cancer Vaccines
Kaidre Bendjama
Show Less

See Also

Discover More
What is the Intrinsic Value of one TNG stock?

The intrinsic value of one TNG stock under the Base Case scenario is 1.098 EUR.

Is TNG stock undervalued or overvalued?

Compared to the current market price of 0.788 EUR, Transgene SA is Undervalued by 28%.

Back to Top